Collegium Pharmaceutical Stock News

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people liv

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wal

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago.

– Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income

Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fa

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving t

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.

Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.

The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small

Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.